A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis.
Mollee P, Tiley C, Cunningham I, Moore J, Prince HM, Cannell P, Gibbons S, Tate J, Paul S, Mar Fan H, Gill DS.
Mollee P, et al. Among authors: paul s.
Br J Haematol. 2012 Jun;157(6):766-9. doi: 10.1111/j.1365-2141.2012.09080.x. Epub 2012 Mar 6.
Br J Haematol. 2012.
PMID: 22390735
Free article.
Clinical Trial.
No abstract available.